Content Marketing Director
+13 year(s) experience
Her key achievements include managing, and producing, thought leadership, showcasing the individual and synergistic strengths of Pharma Intelligence analysts and services while overseeing content marketing strategy.
She joined Citeline, part of Informa, in 2007 as a Trialtrove analyst, and was responsible for the editorial content of Trialtrove for infectious diseases and genitourinary conditions, specializing in HIV and HCV. After regularly contributing to Citeline’s Thought Leadership, Doro began managing the program in 2015.
Before Informa, she spent 3 years at the University of California, San Francisco’s Women’s Global Health Imperative and managed Phase III HIV prevention clinical trials based in Zimbabwe. She has an MPH specializing in infectious diseases from UC Berkeley, and a BA in English Literature from the University of Pennsylvania.
For a detailed look at the statistics and trends surrounding clinical trials initiated in 2017, we invite you to download 2017 Clinical Trials Roundup: The Evolution Continues. Using a wealth of trial data from Trialtrove, this information-packed white paper provides a detailed analysis of Phase I–III clinical trials that were initiated last year.
The fourth annual CARE Awards returned to Boston, Massachusetts 2 May to once again recognize and commend key achievements across the spectrum of drug development that took place in 2018.
The CARE Awards ceremony was held on April 25th at the Boston Harbor Hotel to pay tribute to the people driving the advances in drug development and their commitments to advancing human health. The ceremony was once again hosted by multi-media journalist, Janet Wu, former Anchor and Health Reporter for Boston’s NBC station and adjunct professor at Emerson College
Last year, Pharma Intelligence launched the Clinical and Research Excellence (CARE) Awards to recognize and honor the vital contributions of those making a difference within clinical R&D.
This analysis takes a closer look at Phase II-III studies in HIV positive patients in order to determine what effect collaboration has on enrollment trends in clinical trials evaluating antiretroviral treatment, if any.
Transparency in clinical research has been a long standing issue, especially when it comes to reporting results of completed studies.